{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:d055d725-8119-4d51-9a01-d4a42051243e", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-08-31T04:03:34.274885Z", "firstcreated": "2026-08-31T04:02:22.728400Z", "pubstatus": "usable", "urgency": 5, "language": "en", "headline": "Eplontersen shows benefit in transthyretin amyloid cardiomyopathy only without stabilizers", "byline": "Logan Weston", "located": "United States", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Science Official", "usageterms": "Monitoring item. Headline, short extract and the source link may be shown. Do not republish the full text.", "description_text": "A secondary analysis of the phase 3 CARDIOTTRansform trial presented at the 2026 ESC Congress found that the antisense oligonucleotide eplontersen improved outcomes in transthyretin amyloid cardiomyopathy patients not taking transthyretin stabilizers at baseline, but showed no such benefit in those already on stabilizers.", "altids": {"mosaic": "d055d725-8119-4d51-9a01-d4a42051243e", "story": "988b1d95-5c0c-4826-a676-57ee2ffa8161", "slug": "eplontersen-shows-benefit-in-transthyretin-amyloid-cardiomyopathy-only-without-stabilizers"}, "subject": [{"name": "Health", "rel": "direct", "literal": "health", "code": "medtop:07000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/07000000"}], "place": [{"name": "United States", "literal": "us", "code": "US", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "body_text": "A secondary analysis of the phase 3 CARDIOTTRansform trial presented at the 2026 ESC Congress found that the antisense oligonucleotide eplontersen improved outcomes in transthyretin amyloid cardiomyopathy patients not taking transthyretin stabilizers at baseline, but showed no su", "extra_body_note": "Extract only — see rights.class = link_only.", "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:002566f3-7ec0-4a24-affe-c698a94240d0", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial", "description_text": "Eplontersen shows benefit in transthyretin amyloid cardiomyopathy only without stabilizers", "copyrightholder": "en.wikipedia.org", "copyrightnotice": "Amyloid cardiomyopathy", "usageterms": "File-level licence not yet resolved from Commons; fetch the original for exact terms.", "altids": {"wireva": "002566f3-7ec0-4a24-affe-c698a94240d0"}, "extra": {"wireva:delivery_mode": "preview_and_link", "wireva:rights": {"licence": "Wikimedia — licence per file", "licence_url": "https://commons.wikimedia.org/wiki/Commons:Reusing_content_outside_Wikimedia", "licence_raw": "Wikipedia page image", "licence_verified_at": "2026-08-31T04:03:34.289256Z", "attribution_required": true, "attribution_text": "Amyloid cardiomyopathy", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "en.wikipedia.org", "source_url": "https://en.wikipedia.org/wiki/Amyloid_cardiomyopathy", "source_page_url": "https://en.wikipedia.org/wiki/Amyloid_cardiomyopathy", "our_page_url": "https://scienceofficial.org/medicine/eplontersen-shows-benefit-in-transthyretin-amyloid-cardiomyopathy-only-without-stabilizers/"}, "wireva:role": "lead"}, "renditions": {"preview": {"href": "https://nbg1.your-objectstorage.com/ckln/image-assets/e6d42d38538bc425d17ad450859af7ea62b7c99f000441de78f02a7fa0f1dd4d.jpg", "mimetype": "image/jpeg", "width": 600, "height": 406}, "source": {"href": "https://en.wikipedia.org/wiki/Amyloid_cardiomyopathy", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:988b1d95-5c0c-4826-a676-57ee2ffa8161", "slug": "eplontersen-shows-benefit-in-transthyretin-amyloid-cardiomyopathy-only-without-stabilizers-20260831", "status": "developing", "languages": ["en"], "item_count": 1, "is_breaking": false}, "wireva:rights": {"class": "link_only", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Science Official", "canonical_required": true, "canonical_url": "https://scienceofficial.org/medicine/eplontersen-shows-benefit-in-transthyretin-amyloid-cardiomyopathy-only-without-stabilizers/", "linkback_required": true, "licence": "", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 280, "decided_by_rule": "derivation_failed", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "single_source", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.", "independence_check": {"status": "failed", "score": 0.788, "checked_at": "2026-08-31T04:03:34.286472Z"}}, "wireva:publication": {"name": "Science Official", "domain": "scienceofficial.org", "country": "US", "url": "https://scienceofficial.org/medicine/eplontersen-shows-benefit-in-transthyretin-amyloid-cardiomyopathy-only-without-stabilizers/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/d055d725-8119-4d51-9a01-d4a42051243e", "html": "https://wireva.mib.news/item/d055d725-8119-4d51-9a01-d4a42051243e/eplontersen-shows-benefit-in-transthyretin-amyloid-cardiomyopathy-only-without-stabilizers/", "story": "https://wireva.mib.news/story/eplontersen-shows-benefit-in-transthyretin-amyloid-cardiomyopathy-only-without-stabilizers-20260831/"}, "wireva:metrics": {"word_count": 498, "char_count": 3627, "reading_time_seconds": 259}}}